title: Intra-arterial chemotherapy is reliable in preventing high-risk superficial bladder cancer from recurrence and progression.
abstract: The purpose of this prospective study was to evaluate the therapeutic effects of intra-arterial chemotherapy in preventing high-risk superficial bladder cancer from recurrence and progression. from may 2003 to December 2007, 52 patients were divided randomly into 2 groups. Twenty-five patients were given intra-arterial chemotherapy with gemcitabine and cisplatin, and 27 patients received intravesical instillation with epirubicin. After 6-67 months of follow-up (median, 40 months), the overall recurrence-free rates of the intra-arterial chemotherapy and intravesical instillation groups were 83.3% and 33.4%, respectively (p=0.001 log rank). Tumor progression was not found in the intra-arterial chemotherapy group while 7 patients in the intravesical instillation group had tumor progression. The overall tumor progression-free rates were 100% and 58.5%, respectively (p=0.009 log rank). The patients with functional bladders were 100% and 81.5% in the intra-arterial chemotherapy and intravesical instillation groups after 67 months of follow-up, respectively. In conclusion, intra-arterial chemotherapy is more effective than intravesical instillation in preventing high-risk superficial bladder cancer from recurrence and progression.
authors.affiliation: State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, PR China.
authors.forename: M K
authors.initials: MK
authors.lastname: Chen
authors.forename: Z K
authors.initials: ZK
authors.lastname: Qin
authors.forename: F J
authors.initials: FJ
authors.lastname: Zhou
authors.forename: H
authors.initials: H
authors.lastname: Han
authors.forename: Z W
authors.initials: ZW
authors.lastname: Liu
authors.forename: Y H
authors.initials: YH
authors.lastname: Li
authors.forename: K
authors.initials: K
authors.lastname: Yao
authors.forename: G L
authors.initials: GL
authors.lastname: Hou
authors.forename: Y L
authors.initials: YL
authors.lastname: Ye
authors.forename: Z L
authors.initials: ZL
authors.lastname: Zhang
authors.forename: H
authors.initials: H
authors.lastname: Tu
authors.forename: X Q
authors.initials: XQ
authors.lastname: Zhang
authors.forename: K S
authors.initials: KS
authors.lastname: Lu
authors.forename: Z W
authors.initials: ZW
authors.lastname: Yang
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D015251:Epirubicin